Welcome to our dedicated page for Bruker SEC filings (Ticker: BRKRP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Bruker Corporation 6.375% Mandatory Convertible Preferred Stock (BRKRP) filings page on Stock Titan is designed to organize and interpret regulatory information related to this preferred equity and its issuer, Bruker Corporation. While no specific SEC filings are listed here in the available data, Bruker’s public communications provide important context for understanding BRKRP as a mandatory convertible preferred security with a stated dividend rate of 6.375%.
In its announcements, Bruker has disclosed a quarterly cash dividend of $3.6745 per share on its 6.375% Mandatory Convertible Preferred Stock, Series A. Regulatory filings associated with such securities typically include the original registration statements and prospectus describing the preferred stock terms, including dividend provisions, conversion mechanics, and rights relative to common stock. Periodic reports often discuss capital structure, preferred stock dividends, and any changes affecting holders of BRKRP.
For a company like Bruker, which emphasizes high-performance scientific instruments and analytical and diagnostic solutions, core SEC filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q can also provide narrative and quantitative detail on its operations in post-genomic life science research, applied and biopharma applications, microscopy and nanoanalysis, industrial and cleantech research, semiconductor metrology, and clinical and molecular diagnostics. These documents help place the BRKRP preferred stock within the broader financial and operational picture of the issuer.
On Stock Titan, AI-powered tools can assist in summarizing lengthy filings, highlighting sections that relate to preferred stock terms, dividend policies, and capital structure, as well as identifying disclosures relevant to Bruker’s scientific and diagnostic activities. This can help readers more quickly locate information that matters for evaluating BRKRP and understanding how regulatory disclosures reflect Bruker’s business and financing choices.
Bruker Corp executive Mark Munch reported an option exercise and related share sale. He exercised stock options to acquire 2,000 shares of Common Stock at $22.19 per share and on the same day sold 2,000 shares in an open‑market transaction at $54.76 per share.
The filing notes that the sales were made under a pre‑arranged Rule 10b5‑1 trading plan. Following these transactions, Munch directly holds 128,443 shares of Bruker Common Stock.
Bruker Corp executive Mark Munch reported an option exercise and related share sale. He exercised stock options to acquire 2,000 shares of Common Stock at $22.19 per share and on the same day sold 2,000 shares in an open‑market transaction at $54.76 per share.
The filing notes that the sales were made under a pre‑arranged Rule 10b5‑1 trading plan. Following these transactions, Munch directly holds 128,443 shares of Bruker Common Stock.
Broker Technologies, Inc. (BRKR) notice of proposed sale of 2,000 shares of Common Stock via a stock option exercise to the issuer for cash, dated 06/15/2026. The filing lists prior sales by Mark R. Munch of 2,000 shares on 05/15/2026 for $87,800.00 and 2,000 shares on 04/15/2026 for $79,800.00.
The notice describes the proposed sale method as an exercise through Morgan Stanley Smith Barney LLC and records the transaction party as the issuer. This is an affiliate resale notice under standard procedures and the excerpt does not state any proceeds recipient beyond the issuer or broader strategic implications.
Broker Technologies, Inc. (BRKR) notice of proposed sale of 2,000 shares of Common Stock via a stock option exercise to the issuer for cash, dated 06/15/2026. The filing lists prior sales by Mark R. Munch of 2,000 shares on 05/15/2026 for $87,800.00 and 2,000 shares on 04/15/2026 for $79,800.00.
The notice describes the proposed sale method as an exercise through Morgan Stanley Smith Barney LLC and records the transaction party as the issuer. This is an affiliate resale notice under standard procedures and the excerpt does not state any proceeds recipient beyond the issuer or broader strategic implications.
Bruker Corporation has filed a shelf registration on Form S-3 to register an unlimited aggregate amount of securities for offer and resale from time to time, including common stock, preferred stock, debt securities, warrants, units, depositary shares, subscription rights and purchase contracts. Selling stockholders may also offer shares pursuant to supplements.
The prospectus states that specific terms, amounts, offering prices and whether proceeds will be received by Bruker or selling holders will be set forth in prospectus supplements; unless a supplement states otherwise, proceeds from sales by selling stockholders will not be received by Bruker.
Bruker Corporation has filed a shelf registration on Form S-3 to register an unlimited aggregate amount of securities for offer and resale from time to time, including common stock, preferred stock, debt securities, warrants, units, depositary shares, subscription rights and purchase contracts. Selling stockholders may also offer shares pursuant to supplements.
The prospectus states that specific terms, amounts, offering prices and whether proceeds will be received by Bruker or selling holders will be set forth in prospectus supplements; unless a supplement states otherwise, proceeds from sales by selling stockholders will not be received by Bruker.
Bruker Corporation filed an amended current report to add missing Inline XBRL tags on the cover page for its 6.375% Mandatory Convertible Preferred Stock, Series A. The amendment does not change any prior disclosures.
At the 2026 Annual Meeting held on May 21, 2026, stockholders elected three Class II directors to terms ending at the 2029 Annual Meeting. Laura A. Francis received 136,149,316 votes for and 4,841,094 withheld, John J. Phillips received 139,036,356 for and 1,954,054 withheld, and Hermann F. Requardt received 129,777,851 for and 11,212,559 withheld.
Stockholders approved, on an advisory basis, 2025 compensation for named executive officers with 127,190,553 votes for, 5,748,270 against and 60,390 abstentions. They also ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 by 138,544,738 votes for, 618,216 against and 29,744 abstentions.
Bruker Corporation filed an amended current report to add missing Inline XBRL tags on the cover page for its 6.375% Mandatory Convertible Preferred Stock, Series A. The amendment does not change any prior disclosures.
At the 2026 Annual Meeting held on May 21, 2026, stockholders elected three Class II directors to terms ending at the 2029 Annual Meeting. Laura A. Francis received 136,149,316 votes for and 4,841,094 withheld, John J. Phillips received 139,036,356 for and 1,954,054 withheld, and Hermann F. Requardt received 129,777,851 for and 11,212,559 withheld.
Stockholders approved, on an advisory basis, 2025 compensation for named executive officers with 127,190,553 votes for, 5,748,270 against and 60,390 abstentions. They also ratified PricewaterhouseCoopers LLP as independent auditor for fiscal 2026 by 138,544,738 votes for, 618,216 against and 29,744 abstentions.
Bruker Corporation reported the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected three Class II directors — Laura A. Francis, John J. (Jack) Phillips, and Hermann F. Requardt, Ph.D. — each to serve three-year terms ending at the 2029 annual meeting.
Stockholders approved, on an advisory basis, the 2025 compensation of the company’s named executive officers, with 127,190,553 votes for, 5,748,270 against, and 60,390 abstentions, plus 6,193,485 broker non-votes. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026, with 138,544,738 votes for, 618,216 against, and 29,744 abstentions.
Bruker Corporation reported the results of its 2026 Annual Meeting of Stockholders held on May 21, 2026. Stockholders elected three Class II directors — Laura A. Francis, John J. (Jack) Phillips, and Hermann F. Requardt, Ph.D. — each to serve three-year terms ending at the 2029 annual meeting.
Stockholders approved, on an advisory basis, the 2025 compensation of the company’s named executive officers, with 127,190,553 votes for, 5,748,270 against, and 60,390 abstentions, plus 6,193,485 broker non-votes. They also ratified the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal 2026, with 138,544,738 votes for, 618,216 against, and 29,744 abstentions.
Bruker Corp director Bernard Thierry reported an equity award of 2,886 shares of Common Stock in the form of Restricted Stock Units (RSUs). The RSUs were granted at no cash cost to him and represent stock-based compensation.
The RSUs will vest in one installment on May 15, 2027, and on that date each RSU will automatically convert into one share of Bruker Common Stock. Following this grant, Thierry holds 2,886 shares directly, reflecting this new award only and indicating a routine compensation-related acquisition rather than an open-market purchase.
Bruker Corp director Bernard Thierry reported an equity award of 2,886 shares of Common Stock in the form of Restricted Stock Units (RSUs). The RSUs were granted at no cash cost to him and represent stock-based compensation.
The RSUs will vest in one installment on May 15, 2027, and on that date each RSU will automatically convert into one share of Bruker Common Stock. Following this grant, Thierry holds 2,886 shares directly, reflecting this new award only and indicating a routine compensation-related acquisition rather than an open-market purchase.
Bruker Corporation announced that its Board of Directors has declared a quarterly cash dividend on its common stock of $0.05 per share. The dividend was declared on May 14, 2026 and will be paid on July 7, 2026 to shareholders of record at the close of business on June 22, 2026. The dividend applies to Bruker’s common stock with a par value of $0.01 per share.
Bruker Corporation announced that its Board of Directors has declared a quarterly cash dividend on its common stock of $0.05 per share. The dividend was declared on May 14, 2026 and will be paid on July 7, 2026 to shareholders of record at the close of business on June 22, 2026. The dividend applies to Bruker’s common stock with a par value of $0.01 per share.
Notice of proposed sale of common stock under Rule 144. The filing lists 2,000 shares proposed for sale via a stock option exercise on 05/15/2026 with payment indicated as cash. The record includes two prior sales of 2,000 shares each on 04/15/2026 and 03/13/2026 with proceeds of $79,800 and $70,880, respectively.
Notice of proposed sale of common stock under Rule 144. The filing lists 2,000 shares proposed for sale via a stock option exercise on 05/15/2026 with payment indicated as cash. The record includes two prior sales of 2,000 shares each on 04/15/2026 and 03/13/2026 with proceeds of $79,800 and $70,880, respectively.
Bruker Corp reports that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd and Orbis Investment Management (U.S.), L.P. together beneficially own 17,940,076 shares of Common Stock, equal to 11.8% of the class as disclosed in this Schedule 13G/A amendment.
The filing breaks down voting and dispositive power: Orbis Investment Management Ltd holds 16,852,868 shares of sole voting and dispositive power; Orbis Investment Management (U.S.), L.P. holds 1,058,886 shares; Allan Gray Australia Pty Ltd holds 28,322 shares. The reporting persons state they do not treat themselves as a Section 13(d)(3) group and each disclaims ownership of shares reported by the others.
Bruker Corp reports that Orbis Investment Management Ltd, Allan Gray Australia Pty Ltd and Orbis Investment Management (U.S.), L.P. together beneficially own 17,940,076 shares of Common Stock, equal to 11.8% of the class as disclosed in this Schedule 13G/A amendment.
The filing breaks down voting and dispositive power: Orbis Investment Management Ltd holds 16,852,868 shares of sole voting and dispositive power; Orbis Investment Management (U.S.), L.P. holds 1,058,886 shares; Allan Gray Australia Pty Ltd holds 28,322 shares. The reporting persons state they do not treat themselves as a Section 13(d)(3) group and each disclaims ownership of shares reported by the others.
Bruker Corporation reported Q1 2026 revenue of $823.4 million, slightly higher than $801.4 million a year earlier, with growth in both product and service revenue. Gross profit was $379.8 million, but higher operating expenses and restructuring and impairment charges reduced operating income to $10.2 million from $31.8 million.
Net income attributable to Bruker was $14.4 million, but after $10.9 million of preferred dividends, net income to common shareholders was $3.5 million, or $0.02 per diluted share, down from $0.11. Operating cash flow improved to $71.2 million, while cash fell as Bruker repaid $181.3 million of long-term debt and invested in acquisitions.
Bruker completed the acquisition of the remaining 60% of Tofwerk, recognizing total consideration of $81.0 million and a $12.2 million non-taxable gain on remeasuring its prior stake. The company recorded $17.8 million of restructuring costs and $12.9 million of long-lived asset impairments, mainly in the BSI NANO and CALID segments, and continued a corporate-wide cost program expected to finish in 2026.
Bruker Corporation reported Q1 2026 revenue of $823.4 million, slightly higher than $801.4 million a year earlier, with growth in both product and service revenue. Gross profit was $379.8 million, but higher operating expenses and restructuring and impairment charges reduced operating income to $10.2 million from $31.8 million.
Net income attributable to Bruker was $14.4 million, but after $10.9 million of preferred dividends, net income to common shareholders was $3.5 million, or $0.02 per diluted share, down from $0.11. Operating cash flow improved to $71.2 million, while cash fell as Bruker repaid $181.3 million of long-term debt and invested in acquisitions.
Bruker completed the acquisition of the remaining 60% of Tofwerk, recognizing total consideration of $81.0 million and a $12.2 million non-taxable gain on remeasuring its prior stake. The company recorded $17.8 million of restructuring costs and $12.9 million of long-lived asset impairments, mainly in the BSI NANO and CALID segments, and continued a corporate-wide cost program expected to finish in 2026.